Definitive Healthcare Names Clay Ritchey CEO as Advent Offers $1.02 Take-Private Bid
A special committee is reviewing the offer.
/ 1648 items
#XY↓
TScan Pivots to In-Body T-Cell Therapy for Solid Tumors, Cuts 75% of Staff
TScan is shifting to in vivo TCR-T for solid tumors, pausing Phase 3 enrollment in TSC-101 and cutting about 75% of staff. Cash is expected to last into Q4 2027.
Teva’s Anti-IL-15 Antibody Meets Main Goal in Celiac Disease Study
Teva’s TEV ’408 met its Phase 2a primary endpoint in celiac disease, limiting gluten-induced intestinal damage after one subcutaneous dose.
William Blair Restarts uniQure Coverage at $73, Sees Path for Huntington’s Gene Therapy
William Blair restarts QURE coverage with a $73 estimate, citing a clearer FDA path for AMT-130 in Huntington’s and cash funding into 2030.
Enovis Stock Slides After €155 Million eCential Robotics Offer
Near-term dilution and leverage outweighed the longer robotics strategy.
Invivyd Promotes Marc Elia to CEO and Maps Dual Path for VYD2311 Data
Cantor keeps Overweight and a $10 target after the stock drop.